Today, Washington state stands at the threshold of receiving a significant financial windfall as part of a massive $720 million opioid settlement with eight key drug manufacturers. These companies have been implicated in fueling the opioid crisis that has gripped the nation, and the compensation they're due to pay reflects a widespread push for accountability.
According to an announcement by the Washington State Attorney General's office, the Evergreen State could receive upwards of $16 million. This sum will be split evenly, with half entrusted to the state government's coffers and the other half distributed among local governments, each dollar earmarked for initiatives aimed at fighting opioid abuse. The specific allocation will depend upon how many local entities sign on to the settlements, and other criteria delineated in the settlement agreements.
The companies involved have been ordered to pay varying amounts, staggered across different time frames. Mylan (now part of Viatris) has the largest bill at nearly $284.5 million over nine years. Others, like Hikma, will pay $95.8 million over one to four years, and Amneal pledges $71.8 million to be paid over a decade. Apotex, Alvogen, and Zydus are making their contributions in a single year, with Apotex at $63.7 million, Alvogen about $18.7 million, and Zydus nearly $15 million. Indivior will distribute $38 million over four years, while Sun contributes almost $31 million, payable within one to four years.
Seven out of the eight companies have been given a strict prohibition against the marketing and promotion of opioids. What's more, the manufacture or the sale of any product containing over 40 milligrams of oxycodone per pill is no longer permitted for these companies, and they are required to establish robust systems to monitor and report any suspicious orders. Indivior, on the other hand, has been barred from manufacturing or selling opioid products for the next decade yet will retain the ability to market and sell treatments for opioid use disorder.
This recent settlement adds to Washington state's growing funds allocated for addressing the opioid crisis. Since 2022, the state has amassed $1.3 billion through various settlements. The continuous influx of financial resources signifies a proactive stance not merely penalizing pharmaceutical companies but also bolstering the efforts to heal communities ravaged by addiction.
